TY - JOUR A1 - Adam, Christian A1 - Baeurle, Anne A1 - Brodsky, Jeffrey L. A1 - Schrama, David A1 - Wipf, Peter A1 - Becker, Jürgen Christian A1 - Houben, Roland T1 - The HSP70 Modulator MAL3-101 Inhibits Merkel Cell Carcinoma N2 - Merkel Cell Carcinoma (MCC) is a rare and highly aggressive neuroendocrine skin cancer for which no effective treatment is available. MCC represents a human cancer with the best experimental evidence for a causal role of a polyoma virus. Large T antigens (LTA) encoded by polyoma viruses are oncoproteins, which are thought to require support of cellular heat shock protein 70 (HSP70) to exert their transforming activity. Here we evaluated the capability of MAL3-101, a synthetic HSP70 inhibitor, to limit proliferation and survival of various MCC cell lines. Remarkably, MAL3-101 treatment resulted in considerable apoptosis in 5 out of 7 MCC cell lines. While this effect was not associated with the viral status of the MCC cells, quantitative mRNA expression analysis of the known HSP70 isoforms revealed a significant correlation between MAL3-101 sensitivity and HSC70 expression, the most prominent isoform in all cell lines. Moreover, MAL3-101 also exhibited in vivo antitumor activity in an MCC xenograft model suggesting that this substance or related compounds are potential therapeutics for the treatment of MCC in the future. KW - apoptosis KW - cancer treatment KW - cell staining KW - cultured fibroplasts KW - heat shock response KW - membrans proteins KW - polymerase chain reaction Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-112795 ER - TY - JOUR A1 - Barres, B. A. A1 - Schmid, R. A1 - Sendtner, Michael A1 - Raff, Martin C. T1 - Multiple extracellular signals are required for long-term oligodendrocyte survival N2 - We showed previously that oligodendrocytes and their precursors require continuous signalling by protein trophic factors to avoid programmed cell death in culture. Here we show that three classes of such trophic factors promote oligodendrocyte survival in vitro: (1) insulin and insulin-like growth factors (IGFs), (2) neurotrophins, particularly neurotrophin-3 (NT -3), and (3) ciliary-neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and interleukin 6 (IL-6). A single factor, or combinations of factors within the same class, promote only short-term survival of oligodendrocytes and their precursors, while combinations of factors from different classes promote survival additively. Long-term survival of oligodendrocytes in vitro requires at least one factor from each class, suggesting that multiple signals may be required for long-term oligodendrocyte survival in vivo. We also show that CNTF promotes oligodendrocyte survival in vivo, that platelet-derived growth factor (PDGF) can promote the survival of oligodendrocyte precursors in vitro by acting on a novel, very high affinity PDGF receptor, and that, in addition to its effect on survival, NT-3 is a potent mitogen for oligodendrocyte precursor cells. KW - neurotrophins KW - programmed cell death KW - apoptosis KW - ciliary-neurotrophic factor KW - interleukin 6 KW - insulin KW - insulin-likegrowth factor I Y1 - 1993 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-42644 ER - TY - JOUR A1 - Bartel, Karin A1 - Pein, Helmut A1 - Popper, Bastian A1 - Schmitt, Sabine A1 - Janaki-Raman, Sudha A1 - Schulze, Almut A1 - Lengauer, Florian A1 - Koeberle, Andreas A1 - Werz, Oliver A1 - Zischka, Hans A1 - Müller, Rolf A1 - Vollmar, Angelika M. A1 - Schwarzenberg, Karin von T1 - Connecting lysosomes and mitochondria – a novel role for lipid metabolism in cancer cell death JF - Cell Communication and Signaling N2 - Background The understanding of lysosomes has been expanded in recent research way beyond their view as cellular trash can. Lysosomes are pivotal in regulating metabolism, endocytosis and autophagy and are implicated in cancer. Recently it was discovered that the lysosomal V-ATPase, which is known to induce apoptosis, interferes with lipid metabolism in cancer, yet the interplay between these organelles is poorly understood. Methods LC-MS/MS analysis was performed to investigate lipid distribution in cells. Cell survival and signaling pathways were analyzed by means of cell biological methods (qPCR, Western Blot, flow cytometry, CellTiter-Blue). Mitochondrial structure was analyzed by confocal imaging and electron microscopy, their function was determined by flow cytometry and seahorse measurements. Results Our data reveal that interfering with lysosomal function changes composition and subcellular localization of triacylglycerids accompanied by an upregulation of PGC1α and PPARα expression, master regulators of energy and lipid metabolism. Furthermore, cardiolipin content is reduced driving mitochondria into fission, accompanied by a loss of membrane potential and reduction in oxidative capacity, which leads to a deregulation in cellular ROS and induction of mitochondria-driven apoptosis. Additionally, cells undergo a metabolic shift to glutamine dependency, correlated with the fission phenotype and sensitivity to lysosomal inhibition, most prominent in Ras mutated cells. Conclusion This study sheds mechanistic light on a largely uninvestigated triangle between lysosomes, lipid metabolism and mitochondrial function. Insight into this organelle crosstalk increases our understanding of mitochondria-driven cell death. Our findings furthermore provide a first hint on a connection of Ras pathway mutations and sensitivity towards lysosomal inhibitors. KW - lysosome KW - V-ATPase KW - mitochondria KW - fission KW - apoptosis KW - lipid metabolism KW - cardiolipin Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-221524 VL - 17 ER - TY - JOUR A1 - Becker, Philip P. A1 - Rau, Monika A1 - Schmitt, Johannes A1 - Malsch, Carolin A1 - Hammer, Christian A1 - Bantel, Heike A1 - Müllhaupt, Beat A1 - Geier, Andreas T1 - Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis JF - PLoS ONE N2 - Objectives Liver biopsies are the current gold standard in non-alcoholic steatohepatitis (NASH) diagnosis. Their invasive nature, however, still carries an increased risk for patients' health. The development of non-invasive diagnostic tools to differentiate between bland steatosis (NAFL) and NASH remains crucial. The aim of this study is the evaluation of investigated circulating microRNAs in combination with new targets in order to optimize the discrimination of NASH patients by non-invasive serum biomarkers. Methods Serum profiles of four microRNAs were evaluated in two cohorts consisting of 137 NAFLD patients and 61 healthy controls. In a binary logistic regression model microRNAs of relevance were detected. Correlation of microRNA appearance with known biomarkers like ALT and CK18-Asp396 was evaluated. A simplified scoring model was developed, combining the levels of microRNA in circulation and CK18-Asp396 fragments. Receiver operating characteristics were used to evaluate the potential of discriminating NASH. Results The new finding of our study is the different profile of circulating miR-21 in NASH patients (p<0.0001). Also, it validates recently published results of miR-122 and miR-192 to be differentially regulated in NAFL and NASH. Combined microRNA expression profiles with CK18-Asp396 fragment level scoring model had a higher potential of NASH prediction compared to other risk biomarkers (AUROC = 0.83, 95% CI = 0.754-0.908; p<0.001). Evaluation of score model for NAFL (Score = 0) and NASH (Score = 4) had shown high rates of sensitivity (91%) and specificity (83%). Conclusions Our study defines candidates for a combined model of miRNAs and CK18-Asp396 levels relevant as a promising expansion for diagnosis and in turn treatment of NASH. KW - fatty liver disease KW - independent marker KW - expression KW - injury KW - NAFLD KW - circulating micrornas KW - caspase activation KW - fibrosis KW - miR-122 KW - apoptosis Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-145147 VL - 10 IS - 11 ER - TY - JOUR A1 - Ben Khaled, Najib A1 - Hammer, Katharina A1 - Ye, Liangtao A1 - Alnatsha, Ahmed A1 - Widholz, Sebastian A. A1 - Piseddu, Ignazio A1 - Sirtl, Simon A1 - Schneider, Julia A1 - Munker, Stefan A1 - Mahajan, Ujjwal Mukund A1 - Montero, Juan José A1 - Griger, Joscha A1 - Mayerle, Julia A1 - Reiter, Florian P. A1 - De Toni, Enrico N. T1 - TRAIL receptor targeting agents potentiate PARP inhibitor efficacy in pancreatic cancer independently of BRCA2 mutation status JF - Cancers N2 - Chemotherapy, the standard treatment for pancreatic ductal adenocarcinoma (PDAC), has only a modest effect on the outcome of patients with late-stage disease. Investigations of the genetic features of PDAC have demonstrated a frequent occurrence of mutations in genes involved in homologous recombination (HR), especially in the breast cancer susceptibility gene 2 (BRCA2). Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, is approved as a maintenance treatment for patients with advanced PDAC with germline BRCA1/2 mutations following a platinum-containing first-line regimen. Limitations to the use of PARP inhibitors are represented by the relatively small proportion of patients with mutations in BRCA1/2 genes and the modest capability of these substances of inducing objective response. We have previously shown that pancreatic cancer with BRCA2 mutations exhibits a remarkably enhanced sensitivity towards tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) receptor-stimulating agents. We thus aimed to investigate the effect of combined treatment with PARP inhibitors and TRAIL receptor-stimulating agents in pancreatic cancer and its dependency on the BRCA2 gene status. The respective effects of TRAIL-targeting agents and the PARP inhibitor olaparib or of their combination were assessed in pancreatic cancer cell lines and patient-derived organoids. In addition, BRCA2-knockout and -complementation models were investigated. The effects of these agents on apoptosis, DNA damage, cell cycle, and receptor surface expression were assessed by immunofluorescence, Western blot, and flow cytometry. PARP inhibition and TRAIL synergized to cause cell death in pancreatic cancer cell lines and PDAC organoids. This effect proved independent of BRCA2 gene status in three independent models. Olaparib and TRAIL in combination caused a detectable increase in DNA damage and a concentration-dependent cell cycle arrest in the G2/M and S cell cycle phases. Olaparib also significantly increased the proportion of membrane-bound death receptor 5. Our results provide a preclinical rationale for the combination of PARP inhibitors and TRAIL receptor agonists for the treatment of pancreatic cancer and suggest that the use of PARP inhibitors could be extended to patients without BRCA2 mutations if used in combination with TRAIL agonists. KW - apoptosis KW - DNA damage KW - pancreatic neoplasms KW - poly(ADP-ribose) polymerase inhibitors KW - TNF-related apoptosis-inducing ligand Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-290884 SN - 2072-6694 VL - 14 IS - 21 ER - TY - JOUR A1 - Cardani, Diego A1 - Sardi, Claudia A1 - La Ferla, Barbara A1 - D'Orazio, Guiseppe A1 - Sommariva, Michele A1 - Marcucci, Fabrizio A1 - Olivero, Daniela A1 - Tagliabue, Elda A1 - Koepsell, Hermann A1 - Nicotra, Francesco A1 - Balsari, Andrea A1 - Rumio, Christiano T1 - Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis JF - Molecular Cancer N2 - Background: Recent studies demonstrated that engagement of sodium glucose transporter 1 (SGLT-1) by orally administered D-glucose protects the intestinal mucosa from lipopolysaccharide (LPS)-induced injury. We tested whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil (5-FU)-induced injury in animal models mimicking acute or chronic mucositis. Methods: Mice were treated intraperitoneally with DXR, alone or in combination with 5-FU, and orally with BLF501, a glucose-derived synthetic compound with high affinity for SGLT-1. Intestinal mucosal epithelium integrity was assessed by histological analysis, cellular proliferation assays, real-time PCR gene expression assays and Western blot assays. Student's t-test (paired two-tailed) and X-2 analyses were used for comparisons between groups. Differences were considered significant at p < 0.05. Results: BLF501 administration in mice treated with DXR and/or 5-FU decreased the injuries to the mucosa in terms of epithelial integrity and cellular proliferative ability. Co-treatment with BLF501 led to a normal expression and distribution of both zonula occludens-1 (ZO-1) and beta-catenin, which were underexpressed after treatment with either chemotherapeutic agent alone. BLF501 administration also restored normal expression of caspase-3 and ezrin/radixin/moesin (ERM), which were overexpressed after treatment with DXR and 5-FU. In SGLT1-/- mice, BLF501 had no detectable effects. BLF501 administration in wild-type mice with growing A431 tumors did not modify antitumor activity of DXR. Conclusions: BLF501-induced protection of the intestinal mucosa is a promising novel therapeutic approach to reducing the severity of chemotherapy-induced mucositis. KW - apoptosis KW - prevention KW - doxorubicin KW - cancer KW - gastrointestinal mucositis KW - SGLT-1 KW - synthetic D-glucose analogy KW - chemotherapy KW - inflammation KW - clinical practice guidelines KW - intestinal mucositis KW - epithelial cells KW - oral mucositis KW - gene-expression Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117352 SN - 1476-4598 VL - 13 IS - 23 ER - TY - JOUR A1 - Chen, Shasha A1 - Lotz, Christopher A1 - Roewer, Norbert A1 - Broscheit, Jens-Albert T1 - Comparison of volatile anesthetic-induced preconditioning in cardiac and cerebral system: molecular mechanisms and clinical aspects JF - European Journal of Medical Research N2 - Volatile anesthetic-induced preconditioning ( APC) has shown to have cardiac and cerebral protective properties in both pre-clinical models and clinical trials. Interestingly, accumulating evidences demonstrate that, except from some specific characters, the underlying molecular mechanisms of APC-induced protective effects in myocytes and neurons are very similar; they share several major intracellular signaling pathways, including mediating mitochondrial function, release of inflammatory cytokines and cell apoptosis. Among all the experimental results, cortical spreading depolarization is a relative newly discovered cellular mechanism of APC, which, however, just exists in central nervous system. Applying volatile anesthetic preconditioning to clinical practice seems to be a promising cardio- and neuroprotective strategy. In this review, we also summarized and discussed the results of recent clinical research of APC. Despite all the positive experimental evidences, large-scale, long-term, more precisely controlled clinical trials focusing on the perioperative use of volatile anesthetics for organ protection are still needed. KW - APC KW - ischemia-reperfusion injury KW - mitochondria KW - apoptosis Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-175509 VL - 23 IS - 10 ER - TY - THES A1 - Chen, Wen T1 - Functional Role of NFATc1 in the Control of Life and Death of Lymphocytes T1 - Die funktionelle Rolle von NFATc1 in der Kontrolle von Leben und Tod von Lymphozyten N2 - In this study, murine ES cells and DT40 B cells were used in parallel to disrupt the Nfatc1 gene and to study the function of individual 6 Nfatc1 isoforms, especially the function of highly inducible NFATc1/aA.We found that the short isoform NFATc1/aA protects DT40 B cells against apoptosis while the long isoform NFATc1/aC appears to enforce apoptosis. DNA microarray studies have shown that in NFATc1" DT40 B cells expressing ectopically human NFATc1/aA, the pkc-theta gene is several fold stronger expressed as in wild type cells. Our results of EMSA (Electrophoretic Mobility Shift Assays) and ChIP (chromatin immuno-precipitation) experiments demonstrated the binding of NFATc1/aA to the pkc-theta promoter in vitro and in vivo. NF-kappa B was also found to bind to the NFATc1 P1-promoter in vitro and in vivo. These data suggest and further prove that NF-kappa B contributes to the induction of the NFATc1 P1 promoter upon activation of T cells. So, NFATc1/aA and NF-kappa B were found to cross-talk in the transcriptional upregulation of their target genes, such as the IL-2 gene and the Nfatc1 gene itself, at multiple steps upon induction of apoptosis. While the pro-apoptotic mechanism of NFATc1s long isoform(s) remains unclear, its corresponding “death partners” are worth further studies. The elucidation of functional roles of NFATc1s short or long isoforms in the control of apoptosis of lymphocytes helps to understand apoptosis regulation, and thereby, the fate of lymphocytes. N2 - In der vorliegenden Studie wurden ES Zellen von der Maus und DT40 B Zellen vom Huhn verwendet, um paralell das Nfatc1 auszuknocken und die Rolle der einzelnen 6 Nfatc1 Isoformen zu studieren, insbesorndere die Funktion des stark induzierbaren NFATc1/aA.Wir konnten feststellen, daß die kurze Isoform NFATc1/aA" DT40 B Zellen gegen Apoptose schützt, während die lange Isoform NFATc1/aC scheinbar die Apoptose verstärkt. DNA Microarray Studien haben gezeigt, daß NFATc1-/-/aA DT40 B Zellen, die humanes NFATc1/aA ektopisch exprimieren, das pkc-theta Gen deutlich stärker exprimieren als in Wildtyp Zellen. Unsere Ergebnisse von EMSA und ChIP Experimenten demonstrieren die Bindung von NFATc1/aA an den pkc-theta Promoter in vitro und in vivo. Für NF-kappa B wurde eine Bindung am Nfatc1 P1 Promoter in vitro und in vivo gezeigt. Dies lässt vermuten, daß NF-kappa B eine Rolle bei der Induktion am Nfatc1 P1 Promoter nach der Aktivierung der T Zelle spielt.Es wurde herausgefunden, daß nach Induktion der Apoptose, NFATc1/aA und NF-kappa B „cross-talk“ an unterschiedlichen Stellen in der transkriptionellen Hochregulierung ihrer Zielgene, wie z.b. dem IL-2 Gen und dem Nfatc1 Gen selbst. Weil die pro-apoptotischen Mechanismen der lange(n) Isoform(en) von NFATc1 unklar bleiben, sollten die korrespondierenden „death partners“ in weiteren Studien untersucht werden. Eine Klärung der funktionellen Rollen der NFATc1 Isoformen in der Kontrolle der Apotose in Lymphozyten wird helfen,die Regulation der Apotose, und damit auch das Schicksal der Lymphozyten, zu verstehen. KW - Lymphozyten KW - NFATc1 KW - Apoptosis KW - lymphocyte KW - NFATc1 KW - apoptosis Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-26675 ER - TY - JOUR A1 - Effenberger, Madlen A1 - Bommert, Kathryn S. A1 - Kunz, Viktoria A1 - Kruk, Jessica A1 - Leich, Ellen A1 - Rudelius, Martina A1 - Bargou, Ralf A1 - Bommert, Kurt T1 - Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation JF - Oncotarget N2 - Multiple Myeloma (MM) is an incurable hematological malignancy affecting millions of people worldwide. As in all tumor cells both glucose and more recently glutamine have been identified as important for MM cellular metabolism, however there is some dispute as to the role of glutamine in MM cell survival. Here we show that the small molecule inhibitor compound 968 effectively inhibits glutaminase and that this inhibition induces apoptosis in both human multiple myeloma cell lines (HMCLs) and primary patient material. The HMCL U266 which does not express MYC was insensitive to both glutamine removal and compound 968, but ectopic expression of MYC imparted sensitivity. Finally, we show that glutamine depletion is reflected by rapid loss of MYC protein which is independent of MYC transcription and post translational modifications. However, MYC loss is dependent on proteasomal activity, and this loss was paralleled by an equally rapid induction of apoptosis. These findings are in contrast to those of glucose depletion which largely affected rates of proliferation in HMCLs, but had no effects on either MYC expression or viability. Therefore, inhibition of glutaminolysis is effective at inducing apoptosis and thus serves as a possible therapeutic target in MM. KW - Multiple Myeloma KW - glutaminase inhibition KW - apoptosis KW - MYC Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170168 VL - 8 IS - 49 ER - TY - JOUR A1 - El-Mesery, M. A1 - Trebing, J. A1 - Schafer, V. A1 - Weisenberger, D. A1 - Siegmund, D. A1 - Wajant, H. T1 - CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells JF - Cell Death & Disease N2 - Targeted cancer therapy concepts often aim at the induction of adjuvant antitumor immunity or stimulation of tumor cell apoptosis. There is further evidence that combined application of immune stimulating and tumor apoptosis-inducing compounds elicits a synergistic antitumor effect. Here, we describe the development and characterization of bifunctional fusion proteins consisting of a single-chain variable fragment (scFv) domain derived from the CD40-specific monoclonal antibody G28-5 that is fused to the N-terminus of stabilized trimeric soluble variants of the death ligand TNF-related apoptosis-inducing ligand (TRAIL). As shown before by us and others for other cell surface antigen-targeted scFv-TRAIL fusion proteins, scFv:G28-TRAIL displayed an enhanced capacity to induce apoptosis upon CD40 binding. Studies with scFv:G28 fusion proteins of TRAIL mutants that discriminate between the two TRAIL death receptors, TRAILR1 and TRAILR2, further revealed that the CD40 binding-dependent mode of apoptosis induction of scFv:G28-TRAIL is operable with each of the two TRAIL death receptors. Binding of scFv:G28-TRAIL fusion proteins to CD40 not only result in enhanced TRAIL death receptor signaling but also in activation of the targeted CD40 molecule. In accordance with the latter, the scFv:G28-TRAIL fusion proteins triggered strong CD40-mediated maturation of dendritic cells. The CD40-targeted TRAIL fusion proteins described in this study therefore represent a novel type of bifunctional fusion proteins that couple stimulation of antigen presenting cells and apoptosis induction. KW - dendritic cells KW - apoptosis KW - CD40 KW - TRAIL Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-128777 VL - 4 IS - e916 ER - TY - JOUR A1 - Fathy, Moustafa A1 - Fawzy, Michael Atef A1 - Hintzsche, Henning A1 - Nikaido, Toshio A1 - Dandekar, Thomas A1 - Othman, Eman M. T1 - Eugenol exerts apoptotic effect and modulates the sensitivity of HeLa cells to cisplatin and radiation JF - Molecules N2 - Eugenol is a phytochemical present in different plant products, e.g., clove oil. Traditionally, it is used against a number of different disorders and it was suggested to have anticancer activity. In this study, the activity of eugenol was evaluated in a human cervical cancer (HeLa) cell line and cell proliferation was examined after treatment with various concentrations of eugenol and different treatment durations. Cytotoxicity was tested using lactate dehydrogenase (LDH) enzyme leakage. In order to assess eugenol’s potential to act synergistically with chemotherapy and radiotherapy, cell survival was calculated after eugenol treatment in combination with cisplatin and X-rays. To elucidate its mechanism of action, caspase-3 activity was analyzed and the expression of various genes and proteins was checked by RT-PCR and western blot analyses. Eugenol clearly decreased the proliferation rate and increased LDH release in a concentration- and time-dependent manner. It showed synergistic effects with cisplatin and X-rays. Eugenol increased caspase-3 activity and the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1β) indicating that eugenol mainly induced cell death by apoptosis. In conclusion, eugenol showed antiproliferative and cytotoxic effects via apoptosis and also synergism with cisplatin and ionizing radiation in the human cervical cancer cell line. KW - eugenol KW - HeLa cells KW - cisplatin KW - radiation KW - apoptosis Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193227 SN - 1420-3049 VL - 24 IS - 21 ER - TY - JOUR A1 - Grebinyk, Anna A1 - Prylutska, Svitlana A1 - Buchelnikov, Anatoliy A1 - Tverdokhleb, Nina A1 - Grebinyk, Sergii A1 - Evstigneev, Maxim A1 - Matyshevska, Olga A1 - Cherepanov, Vsevolod A1 - Prylutskyy, Yuriy A1 - Yashchuk, Valeriy A1 - Naumovets, Anton A1 - Ritter, Uwe A1 - Dandekar, Thomas A1 - Frohme, Marcus T1 - C60 fullerene as an effective nanoplatform of alkaloid Berberine delivery into leukemic cells JF - Pharmaceutics N2 - A herbal alkaloid Berberine (Ber), used for centuries in Ayurvedic, Chinese, Middle-Eastern, and native American folk medicines, is nowadays proved to function as a safe anticancer agent. Yet, its poor water solubility, stability, and bioavailability hinder clinical application. In this study, we have explored a nanosized carbon nanoparticle—C60 fullerene (C60)—for optimized Ber delivery into leukemic cells. Water dispersions of noncovalent C60-Ber nanocomplexes in the 1:2, 1:1, and 2:1 molar ratios were prepared. UV–Vis spectroscopy, dynamic light scattering (DLS), and atomic force microscopy (AFM) evidenced a complexation of the Ber cation with the negatively charged C60 molecule. The computer simulation showed that π-stacking dominates in Ber and C\(_{60}\) binding in an aqueous solution. Complexation with C\(_{60}\) was found to promote Ber intracellular uptake. By increasing C\(_{60}\) concentration, the C\(_{60}\)-Ber nanocomplexes exhibited higher antiproliferative potential towards CCRF-CEM cells, in accordance with the following order: free Ber < 1:2 < 1:1 < 2:1 (the most toxic). The activation of caspase 3/7 and accumulation in the sub-G1 phase of CCRF-CEM cells treated with C\(_{60}\)-Ber nanocomplexes evidenced apoptosis induction. Thus, this study indicates that the fast and easy noncovalent complexation of alkaloid Ber with C\(_{60}\) improved its in vitro efficiency against cancer cells. KW - C60 fullerene KW - Berberine KW - noncovalent nanocomplex KW - UV–Vis KW - DLS and AFM measurements KW - drug release KW - leukemic cells KW - uptake KW - cytotoxicity KW - apoptosis Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193216 SN - 1999-4923 VL - 11 IS - 11 ER - TY - JOUR A1 - Grebinyk, Anna A1 - Prylutska, Svitlana A1 - Chepurna, Oksana A1 - Grebinyk, Sergii A1 - Prylutskyy, Yuriy A1 - Ritter, Uwe A1 - Ohulchanskyy, Tymish Y. A1 - Matyshevska, Olga A1 - Dandekar, Thomas A1 - Frohme, Marcus T1 - Synergy of chemo- and photodynamic therapies with C\(_{60}\) Fullerene-Doxorubicin nanocomplex JF - Nanomaterials N2 - A nanosized drug complex was explored to improve the efficiency of cancer chemotherapy, complementing it with nanodelivery and photodynamic therapy. For this, nanomolar amounts of a non-covalent nanocomplex of Doxorubicin (Dox) with carbon nanoparticle C\(_{60}\) fullerene (C\(_{60}\)) were applied in 1:1 and 2:1 molar ratio, exploiting C\(_{60}\) both as a drug-carrier and as a photosensitizer. The fluorescence microscopy analysis of human leukemic CCRF-CEM cells, in vitro cancer model, treated with nanocomplexes showed Dox’s nuclear and C\(_{60}\)'s extranuclear localization. It gave an opportunity to realize a double hit strategy against cancer cells based on Dox's antiproliferative activity and C\(_{60}\)'s photoinduced pro-oxidant activity. When cells were treated with 2:1 C\(_{60}\)-Dox and irradiated at 405 nm the high cytotoxicity of photo-irradiated C\(_{60}\)-Dox enabled a nanomolar concentration of Dox and C\(_{60}\) to efficiently kill cancer cells in vitro. The high pro-oxidant and pro-apoptotic efficiency decreased IC\(_{50}\) 16, 9 and 7 × 10\(^3\)-fold, if compared with the action of Dox, non-irradiated nanocomplex, and C\(_{60}\)'s photodynamic effect, correspondingly. Hereafter, a strong synergy of therapy arising from the combination of C\(_{60}\)-mediated Dox delivery and C\(_{60}\) photoexcitation was revealed. Our data indicate that a combination of chemo- and photodynamic therapies with C\(_{60}\)-Dox nanoformulation provides a promising synergetic approach for cancer treatment. KW - photodynamic chemotherapy KW - synergistic effect KW - C\(_{60}\) fullerene KW - Doxorubicin KW - nanocomplex KW - leukemic cells KW - apoptosis Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193140 SN - 2079-4991 VL - 9 IS - 11 ER - TY - JOUR A1 - Haferkamp, Sebastian A1 - Hesbacher, Sonja A1 - Weyandt, Gerhard A1 - Vetter-Kauczok, Claudia S. A1 - Becker, Jürgen C. A1 - Motschenbacher, Stephanie A1 - Wobser, Marion A1 - Maier, Melissa A1 - Schmid, Corinna P. A1 - Houben, Roland T1 - p53 regulation by TRP2 is not pervasive in melanoma N2 - p53 is a central tumor suppressor protein and its inhibition is believed to be a prerequisite for cancer development. In approximately 50% of all malignancies this is achieved by inactivating mutations in the p53 gene. However, in several cancer entities, including melanoma, p53 mutations are rare. It has been recently proposed that tyrosinase related protein 2 (TRP2), a protein involved in melanin synthesis, may act as suppressor of the p53 pathway in melanoma. To scrutinize this notion we analyzed p53 and TRP2 expression by immunohistochemistry in 172 melanoma tissues and did not find any correlation. Furthermore, we applied three different TRP2 shRNAs to five melanoma cell lines and could not observe a target specific effect of the TRP2 knockdown on either p53 expression nor p53 reporter gene activity. Likewise, ectopic expression of TRP2 in a TRP2 negative melanoma cell line had no impact on p53 expression. In conclusion our data suggest that p53 repression critically controlled by TRP2 is not a general event in melanoma. KW - melanomas KW - melanoma cell KW - cell staining KW - histology KW - reporter genes KW - apoptosis KW - immunohistochemistry techniques KW - tumor suppressor genes Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-111396 ER - TY - JOUR A1 - Heuser, Christoph A1 - Gotot, Janine A1 - Piotrowski, Eveline Christina A1 - Philipp, Marie-Sophie A1 - Courrèges, Christina Johanna Felicia A1 - Otte, Martin Sylvester A1 - Guo, Linlin A1 - Schmid-Burgk, Jonathan Leo A1 - Hornung, Veit A1 - Heine, Annkristin A1 - Knolle, Percy Alexander A1 - Garbi, Natalio A1 - Serfling, Edgar A1 - Evaristo, César A1 - Thaiss, Friedrich A1 - Kurts, Christian T1 - Prolonged IKK\(\beta\) Inhibition Improves Ongoing CTL Antitumor Responses by Incapacitating Regulatory T Cells JF - Cell Reports N2 - Regulatory T cells (Tregs) prevent autoimmunity but limit antitumor immunity. The canonical NF-\(\kappa\)B signaling pathway both activates immunity and promotes thymic Treg development. Here, we report that mature Tregs continue to require NF-\(\kappa\)B signaling through I\(\kappa\)B-kinase \(\beta\) (IKK\(\beta\)) after thymic egress. Mice lacking IKK\(\beta\) in mature Tregs developed scurfy-like immunopathology due to death of peripheral FoxP3\(^+\) Tregs. Also, pharmacological IKK\(\beta\) inhibition reduced Treg numbers in the circulation by ~50% and downregulated FoxP3 and CD25 expression and STAT5 phosphorylation. In contrast, activated cytotoxic T lymphocytes (CTLs) were resistant to IKK\(\beta\) inhibition because other pathways, in particular nuclear factor of activated T cells (NFATc1) signaling, sustained their survival and expansion. In a melanoma mouse model, IKK\(\beta\) inhibition after CTL cross-priming improved the antitumor response and delayed tumor growth. In conclusion, prolonged IKK\(\beta\) inhibition decimates circulating Tregs and improves CTL responses when commenced after tumor vaccination, indicating that IKK\(\beta\) represents a druggable checkpoint. KW - medicine KW - regulatory T cells KW - NF-\(\kappa\)B pathway KW - tumor vaccination KW - checkpoint inhibition KW - cytotoxic T cells KW - cross-priming KW - apoptosis KW - tumor immunology KW - melanoma Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173643 VL - 21 IS - 3 ER - TY - JOUR A1 - Hintzsche, Henning A1 - Montag, Gracia A1 - Stopper, Helga T1 - Induction of micronuclei by four cytostatic compounds in human hematopoietic stem cells and human lymphoblastoid TK6 cells JF - Scientific Reports N2 - For mutagenicity testing, primary lymphocytes or mammalian cell lines are employed. However, the true target for carcinogenic action of mutagenic chemicals may be stem cells. Since hematopoietic cancers induced by chemical agents originate at the hematopoietic stem cell (HSC) stage and since one of the side effects of chemotherapeutic cancer treatment is the induction of secondary tumors, often leukemias, HSC may be a suitable cell system. We compared the sensitivity of HSC with the genotoxicity testing cell line TK6 for chromosomal mutations. HSC were less sensitive than TK6 cells for the genotoxic effects of the model genotoxins and chemotherapeutic agents doxorubicin, vinblastine, methyl methanesulfonate (MMS) and equally sensitive for mitomycin C (MMC). However, loss of viability after mitomycin C treatment was higher in HSC than in TK6 cells. Among the factors that may influence sensitivity for genomic damage, the generation or response to reactive oxygen species (ROS) and the effectiveness of DNA damage response can be discussed. Here we show that HSC can be used in a standard micronucleus test protocol for chromosomal mutations and that their sensitivity was not higher than that of a classical testing cell line. KW - apoptosis KW - haematopoietic stem cells KW - TK6 cells KW - micronuclei Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176210 VL - 8 IS - 3371 ER - TY - JOUR A1 - Hohenauer, Tobias A1 - Berking, Carola A1 - Schmidt, Andreas A1 - Haferkamp, Sebastian A1 - Senft, Daniela A1 - Kammerbauer, Claudia A1 - Fraschka, Sabine A1 - Graf, Saskia Anna A1 - Irmler, Martin A1 - Beckers, Johannes A1 - Flaig, Michael A1 - Aigner, Achim A1 - Höbel, Sabrina A1 - Hoffmann, Franziska A1 - Hermeking, Heiko A1 - Rothenfusser, Simon A1 - Endres, Stefan A1 - Ruzicka, Thomas A1 - Besch, Robert T1 - The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival JF - EMBO Molecular Medicine N2 - Pigment cells and neuronal cells both are derived from the neural crest. Here, we describe the Pit-Oct-Unc (POU) domain transcription factor Brn3a, normally involved in neuronal development, to be frequently expressed in melanoma, but not in melanocytes and nevi. RNAi-mediated silencing of Brn3a strongly reduced the viability of melanoma cell lines and decreased tumour growth in vivo. In melanoma cell lines, inhibition of Brn3a caused DNA double-strand breaks as evidenced by Mre11/Rad50-containing nuclear foci. Activated DNA damage signalling caused stabilization of the tumour suppressor p53, which resulted in cell cycle arrest and apoptosis. When Brn3a was ectopically expressed in primary melanocytes and fibroblasts, anchorage-independent growth was increased. In tumourigenic melanocytes and fibroblasts, Brn3a accelerated tumour growth in vivo. Furthermore, Brn3a cooperated with proliferation pathways such as oncogenic BRAF, by reducing oncogene-induced senescence in non-malignant melanocytes. Together, these results identify Brn3a as a new factor in melanoma that is essential for melanoma cell survival and that promotes melanocytic transformation and tumourigenesis. KW - oncogene-induced senescence KW - BRN-3A KW - DNA KW - DNA damage KW - tumourigenesis KW - P53 KW - in-vitro KW - neural crest factors KW - family KW - apoptosis KW - melanoma KW - BRAF mutations KW - domain Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122193 SN - 1757-4676 VL - 5 ER - TY - JOUR A1 - Huang, Bei A1 - Belharazem, Djeda A1 - Li, Li A1 - Kneitz, Susanne A1 - Schnabel, Philipp A. A1 - Rieker, Ralf J. A1 - Körner, Daniel A1 - Nix, Wilfried A1 - Schalke, Berthold A1 - Müller-Hermelink, Hans Konrad A1 - Ott, German A1 - Rosenwald, Andreas A1 - Ströbel, Philipp A1 - Marx, Alexander T1 - Anti-apoptotic signature in thymic squamous cell carcinomas – functional relevance of anti-apoptotic BIRC3 expression in the thymic carcinoma cell line 1889c JF - Frontiers in Oncology N2 - The molecular pathogenesis of thymomas and thymic arcinomas (TCs) is poorly understood and results of adjuvant therapy are unsatisfactory in case of metastatic disease and tumor recurrence. For these clinical settings, novel therapeutic strategies are urgently needed. Recently, limited sequencing efforts revealed that a broad spectrum of genes that play key roles in various common cancers are rarely affected in thymomas and TCs, suggesting that other oncogenic principles might be important.This made us re-analyze historic expression data obtained in a spectrumof thymomas and thymic squamous cell carcinomas (TSCCs) with a custom-made cDNA microarray. By cluster analysis, different anti-apoptotic signatures were detected in type B3 thymoma and TSCC, including overexpression of BIRC3 in TSCCs. This was confirmed by qRT-PCR in the original and an independent validation set of tumors. In contrast to several other cancer cell lines, the BIRC3-positive TSCC cell line, 1889c showed spontaneous apoptosis after BIRC3 knock-down. Targeting apoptosis genes is worth testing as therapeutic principle in TSCC. KW - gene expression KW - MTCH2 KW - targeted KW - myasthenia gravis KW - apoptosis KW - thymus KW - thymoma KW - thymic carcinoma Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132214 VL - 3 IS - 316 ER - TY - JOUR A1 - John, Katharina A1 - Franck, Martin A1 - Al Aoua, Sherin A1 - Rau, Monika A1 - Huber, Yvonne A1 - Schattenberg, Joern M. A1 - Geier, Andreas A1 - Bahr, Matthias J. A1 - Wedemeyer, Heiner A1 - Schulze-Osthoff, Klaus A1 - Bantel, Heike T1 - Non-invasive detection of fibrotic NASH in NAFLD patients with low or intermediate FIB-4 JF - Journal of Clinical Medicine N2 - Background: Non-alcoholic steatohepatitis (NASH) and fibrosis are the main prognostic factors in non-alcoholic fatty liver disease (NAFLD). The FIB-4 score has been suggested as an initial test for the exclusion of progressed fibrosis. However, increasing evidence suggests that also NASH patients with earlier fibrosis stages are at risk of disease progression, emphasizing the need for improved non-invasive risk stratification. Methods: We evaluated whether the apoptosis biomarker M30 can identify patients with fibrotic NASH despite low or intermediate FIB-4 values. Serum M30 levels were assessed by ELISA, and FIB-4 was calculated in an exploration (n = 103) and validation (n = 100) cohort of patients with histologically confirmed NAFLD. Results: The majority of patients with low FIB-4 (cut-off value < 1.3) in the exploration cohort revealed increased M30 levels (>200 U/L) and more than 80% of them had NASH, mostly with fibrosis. NASH was also detected in all patients with intermediate FIB-4 (1.3 to 2.67) and elevated M30, from which ~80% showed fibrosis. Importantly, in the absence of elevated M30, most patients with FIB-4 < 1.3 and NASH showed also no fibrosis. Similar results were obtained in the validation cohort. Conclusions: The combination of FIB-4 with M30 enables a more reliable identification of patients at risk for progressed NAFLD and might, therefore, improve patient stratification. KW - apoptosis KW - biomarker KW - fibrosis KW - FIB-4 KW - NAFLD KW - NASH KW - keratin-18 KW - M30 Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-281824 SN - 2077-0383 VL - 11 IS - 15 ER - TY - THES A1 - Jurak, Igor T1 - The molecular mechanism of the Cytomegalovirus species specificity T1 - Molekulare Mechanismen der Cytomegaloviren Arten Spezifizierung N2 - Viruses have undergone a coevolution with their hosts, resulting in a specific adaptation to them. Consequently, many viruses have a limited host range. Occasionally, viruses acquire an adaptive mutation, which allows infection and replication in a different species as shown recently for the human immunodeficiency virus and influenza virus. Cross-species infections are responsible for the majority of emerging and re-emerging viral diseases. However, little is known about the mechanisms that restrict viruses to a certain host species, and the factors viruses need to cross the species barrier and replicate in a different host. Cytomegaloviruses are prototypes of the beta-herpesvirus subfamily and are highly species specific. They replicate only in cells of their own or a closely related species. The molecular mechanism underlying their species specificity is poorly understood and was investigated in this study. An initial observation showed that murine cytomegalovirus (MCMV) can replicate in human 293 and 911 cells, but not in any other human cells tested. Both cell lines are transformed with adenoviral E1 genes that encode a transcriptional transactivator (E1A) and two suppressors of apoptosis (E1B-55k and E1B-19k). This has led to the hypothesis that these functions are required for MCMV replication in human cells. Further analysis revealed that normal human cells died rapidly after infection of caspase-9-mediated apoptosis. Apoptosis induced by MCMV can be suppressed by broad-spectrum caspase inhibitors, and virus replication can be rescued, indicating a major role of caspases in this process. Furthermore, over-expression of a mitochondria-localized inhibitor of apoptosis, a Bcl-2-like protein, prevented apoptosis induced by this virus. Human cells resistant to apoptosis allowed also an efficient MCMV replication. The important role of Bcl-2-like proteins for cytomegalovirus cross-species infections was subsequently confirmed by inserting the corresponding genes, and other inhibitors of apoptosis and control genes into the MCMV genome. Only recombinant viruses expressing a Bcl-2-like protein were able to replicate in human cells. A single gene of human cytomegalovirus encoding a mitochondrial inhibitor of apoptosis was sufficient to allow MCMV replication in human cells. Moreover, the same principle facilitated replication of the rat cytomegalovirus in human cells. Thus, induction of apoptosis limits rodent cytomegalovirus cross-species infection. N2 - Viren durchliefen eine gemeinsame Evolution mit ihren Wirtsorganismen, die zu einer spezifischen Anpassung der Viren an ihren jeweiligen Wirt führte. Als Folge dessen verfügen viele Viren über ein eng begrenztes Wirtsspektrum. Gelegentlich machen Viren Veränderungen durch, die es ihnen erlauben, einen neuen Wirt zu infizieren und in ihm zu replizieren, wie dies in jüngster Vergangenheit beim humanen Immundefizienz-Virus oder beim Grippevirus geschehen ist. Spezies-übergreifende Infektionen sind für die meisten neuen und wiederauftauchenden Viruserkrankungen verantwortlich. Allerdings ist bisher wenig über die Mechanismen bekannt, die Viren auf einen bestimmten Wirt beschränken, und welche Faktoren Viren zur Überwindung der Spezies-Barriere und zur Vermehrung in einer neuen Wirtsspezies benötigen. Cytomegaloviren sind Prototypen der beta-Herpesvirus Unterfamilie und verfügen über eine ausgeprägte Spezies-Spezifität. Sie vermehren sich nur in Zellen der eigenen oder einer eng verwandten Wirtsspezies. Der molekulare Mechanismus, der dieser Spezies-Spezifität zugrunde liegt, ist noch weitgehend unbekannt und stellt deshalb das Thema dieser Arbeit dar. Initiale Beobachtungen zeigten, dass sich das Maus-Cytomegalovirus (MCMV) ausschließlich in menschlichen 293 und 911 Zellen, aber keiner anderen getesteten menschlichen Zelle vermehren ließ. Diese beiden Zelllinien sind mit Adenovirus E1-Genen transformiert, die den Transkriptions-Transaktivator E1A sowie zwei Apoptose-Inhibitoren (E1B-55k und E1B-19k) kodieren. Daher lag die Hypothese nahe, dass diese Funktionen benötigt werden, um eine MCMV-Replikation in menschlichen Zellen zu ermöglichen. Außerdem konnte gezeigt werden, dass normale menschliche Zellen nach Infektion rapide absterben, und zwar durch eine Caspase-9-vermittelte Apoptose. Die Induktion der Apoptose durch MCMV lässt sich durch Caspase-Inhibitoren unterdrücken, wodurch die virale Replikation wiederhergestellt wird. Dies deutet auf eine Schlüsselfunktion der Caspasen für diesen Prozess hin. Durch Überexpression eines mitochondrialen Apoptose-Inhibitors, d.h. eines Bcl-2-ähnlichen Proteins, in menschlichen Zellen ließ sich die Virus-induzierte Apoptose verhindern. Diese Zellen erlaubten ebenfalls eine effiziente MCMV-Replikation. Die Bedeutung Bcl-2-ähnlicher Proteine für die Spezies-übergreifende Cytomegalovirus-Infektion wurde sowohl durch die Integration korrespondierender Gene, alsauch durch die Integration anderer Inhibitioren der Apoptose oder von Kontroll-Genen in das MCMV Genom bestätigt. Nur rekombinante Viren, die ein Bcl-2-ähnliches Protein kodieren, konnten in menschlichen Zellen vermehrt werden. Ein einziges Gen des humanen Cytomegalovirus, das einen mitochondrialen Apoptose-Inhibitor kodiert, reichte aus, um eine MCMV-Replikation in menschlichen Zellen zu ermöglichen. Zusätzlich konnte gezeigt werden, dass dieselben Prinzipien für eine Replikation des Ratten-Cytomegalovirus in menschlichen Zellen gelten. Zusammenfassend kann festgestellt werden, dass die Induktion der Apoptose eine Spezies-übergreifende Infektion bei den Nagetier-Cytomegaloviren einschränkt. KW - Cytomegalie-Virus KW - Art KW - Spezifität KW - Molekularbiologie KW - cytomegaloviren KW - Bcl-2 KW - apoptose KW - cytomegalovirus KW - Bcl-2 KW - apoptosis KW - species specificity Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-19233 ER -